AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17039397 — intervention group
Group type: EXPERIMENTAL
Intervention: CASPAR Youth Services Student Assistance Program (psycho-educational small-group component)
Number of subjects: 0
Study 17039397 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15297828 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mm grafts
Number of subjects: 70
Study 15297828 — intervention group
Group type: COMPARATOR
Intervention: 6- to 8-mm grafts
Number of subjects: 70
Study 11061861 — intervention group
Group type: EXPERIMENTAL
Intervention: (51)Cr-labeled RBCs before surgery
Number of subjects: 5
Study 11061861 — intervention group
Group type: EXPERIMENTAL
Intervention: (51)Cr-labeled RBCs after surgery
Number of subjects: 5
Study 9487834 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil dentifrice containing 1.3% pyrophosphate ion (PPi)
Number of subjects: 150
Study 9487834 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice (Crest Regular)
Number of subjects: 150
Study 8257550 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 1%
Number of subjects: 100
Study 8257550 — intervention group
Group type: COMPARATOR
Intervention: Prilocaine 1%
Number of subjects: 100
Study 3929873 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil (n = 6)
Number of subjects: 21
Study 3929873 — intervention group
Group type: EXPERIMENTAL
Intervention: isosorbide dinitrate (n = 10)
Number of subjects: 21
Study 3929873 — intervention group
Group type: COMPARATOR
Intervention: labetalol (n = 5)
Number of subjects: 21
Study 31615381 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-controlled ventilation
Number of subjects: 12
Study 31615381 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation
Number of subjects: 12
Study 30018370 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricket-containing breakfast foods for 14 days
Number of subjects: 20
Study 30018370 — intervention group
Group type: COMPARATOR
Intervention: Control breakfast foods for 14 days
Number of subjects: 20
Study 30018370 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricket consumption
Number of subjects: 20
Study 26655860 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 35
Study 26655860 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (stretching) exercise
Number of subjects: 35
Study 26655860 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 35
Study 25473213 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydeoxyribonucleotide (PDRN) administered intramuscularly (1 ampule, 3 mL, 5.625 mg, for 5 days) for 2 weeks and perilesionally (1 ampule, 3 mL, 5.625 mg, twice a week) for 4 weeks
Number of subjects: 23
Study 25473213 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 23
Study 22187387 — intervention group
Group type: EXPERIMENTAL
Intervention: 18° camber
Number of subjects: 14
Study 22187387 — intervention group
Group type: EXPERIMENTAL
Intervention: 20° camber
Number of subjects: 14
Study 22187387 — intervention group
Group type: EXPERIMENTAL
Intervention: 15° camber
Number of subjects: 14
Study 22187387 — intervention group
Group type: COMPARATOR
Intervention: 24° camber
Number of subjects: 14
Study 20660401 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation plus early ACL reconstruction
Number of subjects: 121
Study 20660401 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation plus optional delayed ACL reconstruction
Number of subjects: 121
Study 18616658 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.i.d.
Number of subjects: 2667
Study 18616658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2667
Study 16038823 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical Pain Scales (SPS) measuring pain during normal activities
Number of subjects: 2164
Study 16038823 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical Pain Scales (SPS) measuring pain while at rest, pain during normal activities, pain during work or exercise, and pain unpleasantness
Number of subjects: 2164
Study 16038823 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical Pain Scales (SPS) compared with SF-36 health status instrument
Number of subjects: 2164
Study 11379344 — intervention group
Group type: EXPERIMENTAL
Intervention: Bionormalizer (18 g/day for 2 weeks)
Number of subjects: 30
Study 11379344 — intervention group
Group type: COMPARATOR
Intervention: Placebo (flavored sugar)
Number of subjects: 30
Study 11379344 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 9589226 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric formula diet (1,100 +/- 60 kcal/day; 33% protein, 38% carbohydrate, 29% fat)
Number of subjects: 18
Study 9589226 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric formula diet
Number of subjects: 18
Study 8026229 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil-interferon-alpha 2b
Number of subjects: 57
Study 8026229 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil alone
Number of subjects: 57
Study 2917924 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 ppm ozone exposure
Number of subjects: 18
Study 1091127 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate (2 gm. daily)
Number of subjects: 40
Study 1091127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1091127 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofibrate
Number of subjects: 40
Study 31477185 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravid oviposition sticky (GOS) trap and dengue non-structural 1 (NS1) antigen test
Number of subjects: 8
Study 28600953 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualized cognitive therapy (mCT)
Number of subjects: 162
Study 28600953 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral treatment-as-usual (CBTAU)
Number of subjects: 162
Study 26082625 — intervention group
Group type: EXPERIMENTAL
Intervention: QVA149 110/50 μg once daily
Number of subjects: 744
Study 26082625 — intervention group
Group type: COMPARATOR
Intervention: SFC 50/500 μg twice daily
Number of subjects: 744
Study 23365106 — intervention group
Group type: EXPERIMENTAL
Intervention: WL+FAEE (4 g/d Omacor)
Number of subjects: 25
Study 23365106 — intervention group
Group type: COMPARATOR
Intervention: WL (25% energy deficit weight loss diet)
Number of subjects: 25
Study 21274983 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (1000 mg)
Number of subjects: 12
Study 21274983 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NaCl solution)
Number of subjects: 12
Study 18988916 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot virtual reality (VR) system
Number of subjects: 18
Study 18988916 — intervention group
Group type: COMPARATOR
Intervention: Robot alone
Number of subjects: 18
Study 17053350 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir DF
Number of subjects: 105
Study 17053350 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir
Number of subjects: 105
Study 12721716 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue glue
Number of subjects: 0
Study 12721716 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 0
Study 10947692 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 3 mg.kg‐1 and succinylcholine 1 mg.kg‐1 (n = 40)
Number of subjects: 120
Study 10947692 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 3 mg.kg‐1 and alfentanil 10 microg.kg‐1 (n = 40)
Number of subjects: 120
Study 10947692 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% in 60% nitrous oxide in oxygen for 3 min (n = 40)
Number of subjects: 120
Study 10947692 — intervention group
Group type: COMPARATOR
Intervention: Propofol 3 mg.kg‐1 and succinylcholine 1 mg.kg‐1 or Sevoflurane 8%
Number of subjects: 120
Study 8997677 — intervention group
Group type: EXPERIMENTAL
Intervention: CC + GTR
Number of subjects: 80
Study 8997677 — intervention group
Group type: COMPARATOR
Intervention: GTR
Number of subjects: 80
Study 8997677 — intervention group
Group type: COMPARATOR
Intervention: CC
Number of subjects: 80
Study 8997677 — intervention group
Group type: COMPARATOR
Intervention: GFS
Number of subjects: 80
Study 1635933 — intervention group
Group type: EXPERIMENTAL
Intervention: Divitabs (sustained release preparation)
Number of subjects: 20
Study 1635933 — intervention group
Group type: COMPARATOR
Intervention: Normal carbamazepine preparation
Number of subjects: 20
Study 1635933 — intervention group
Group type: EXPERIMENTAL
Intervention: Divitabs
Number of subjects: 20
Study 6234240 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial extract
Number of subjects: 20
Study 29566095 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavendish banana (CAV)
Number of subjects: 20
Study 29566095 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-yellow banana (MIY)
Number of subjects: 20
Study 29566095 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% sugar beverage (SUG)
Number of subjects: 20
Study 29566095 — intervention group
Group type: COMPARATOR
Intervention: Water only (WAT)
Number of subjects: 20
Study 26879069 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rosuvastatin (20 mg/day, n = 18)
Number of subjects: 37
Study 26879069 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rosuvastatin (2.5 mg/day, n = 19)
Number of subjects: 37
Study 26879069 — intervention group
Group type: COMPARATOR
Intervention: Comparison of high-dose vs low-dose rosuvastatin
Number of subjects: 37
Study 25915488 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric bedrest
Number of subjects: 9
Study 25915488 — intervention group
Group type: COMPARATOR
Intervention: Normocaloric ambulatory
Number of subjects: 9
Study 25915488 — intervention group
Group type: COMPARATOR
Intervention: Normocaloric bedrest
Number of subjects: 9
Study 23065047 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antiglaucoma medication
Number of subjects: 581
Study 23065047 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient knowledge of glaucoma
Number of subjects: 581
Study 23065047 — intervention group
Group type: EXPERIMENTAL
Intervention: Forgetfulness
Number of subjects: 581
Study 23065047 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal medicine
Number of subjects: 581
Study 21119128 — intervention group
Group type: EXPERIMENTAL
Intervention: AMSA nerve block
Number of subjects: 28
Study 21119128 — intervention group
Group type: COMPARATOR
Intervention: IONB
Number of subjects: 28
Study 18231908 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab plus cyclophosphamide, vincristine and prednisolone (R-CVP)
Number of subjects: 0
Study 18231908 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, vincristine and prednisolone (CVP)
Number of subjects: 0
Study 16882185 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% ALA-PDT
Number of subjects: 8
Study 16882185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 14636346 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic monotherapy with prednisolone (1 mg/kg/day for 10 days, tapering over 4 days)
Number of subjects: 97
Study 14636346 — intervention group
Group type: COMPARATOR
Intervention: Antiepileptic monotherapy alone
Number of subjects: 97
Study 14636346 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic monotherapy with prednisolone
Number of subjects: 97
Study 10389804 — intervention group
Group type: EXPERIMENTAL
Intervention: IV dexamethasone 10 mg
Number of subjects: 120
Study 10389804 — intervention group
Group type: EXPERIMENTAL
Intervention: IV droperidol 1.25 mg
Number of subjects: 120
Study 10389804 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 120
Study 8678277 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 50
Study 8678277 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 50
Study 1676594 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg
Number of subjects: 72
Study 1676594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg
Number of subjects: 72
Study 1676594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 1676594 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 0.45 mg kg‐1
Number of subjects: 72
Study 1676594 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.08 mg kg‐1
Number of subjects: 72
Study 6350090 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (900 mg/day)
Number of subjects: 20
Study 6350090 — intervention group
Group type: COMPARATOR
Intervention: Lorajmine (600 mg/day)
Number of subjects: 20
Study 6350090 — intervention group
Group type: EXPERIMENTAL
Intervention: After therapy interruption
Number of subjects: 20
Study 2932514 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (a cyclooxygenase inhibitor)
Number of subjects: 12
Study 2932514 — intervention group
Group type: EXPERIMENTAL
Intervention: Dazoxiben hydrochloride (a thromboxane synthase inhibitor)
Number of subjects: 12
Study 2932514 — intervention group
Group type: EXPERIMENTAL
Intervention: BM13.177 (a thromboxane receptor antagonist)
Number of subjects: 12
Study 2932514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29807159 — intervention group
Group type: EXPERIMENTAL
Intervention: NO3‐ supplementation (12 mmol/d)
Number of subjects: 18
Study 29807159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 27537992 — intervention group
Group type: EXPERIMENTAL
Intervention: CF101 2 mg
Number of subjects: 0
Study 27537992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23918683 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 30 mg divided in 2 doses
Number of subjects: 15
Study 23918683 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 30 mg divided in 4 doses
Number of subjects: 15
Study 23918683 — intervention group
Group type: COMPARATOR
Intervention: Patients with AAD
Number of subjects: 15
Study 23918683 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCL11 levels
Number of subjects: 15
Study 22128195 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR stress imaging test
Number of subjects: 120
Study 22128195 — intervention group
Group type: COMPARATOR
Intervention: Provider-selected stress test (stress echo, CMR, cardiac catheterization, nuclear, coronary CT)
Number of subjects: 120
Study 20708169 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical lengths (CLs) ≥25 mm
Number of subjects: 672
Study 20708169 — intervention group
Group type: COMPARATOR
Intervention: Cervical lengths (CLs) <25 mm (no cerclage)
Number of subjects: 672
Study 18726610 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% prednisolone acetate eye drops
Number of subjects: 62
Study 18726610 — intervention group
Group type: COMPARATOR
Intervention: Vehicle eye drop solution
Number of subjects: 62
Study 16029343 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole 150 mg (or 100 mg for children)
Number of subjects: 60
Study 16029343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16029343 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 60
Study 14500148 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (propofol/nitrous oxide/fentanyl)
Number of subjects: 60
Study 14500148 — intervention group
Group type: COMPARATOR
Intervention: Spinal Anesthesia (6 mg bupivacaine and 15 micro g fentanyl)
Number of subjects: 60
Study 14500148 — intervention group
Group type: COMPARATOR
Intervention: Psoas Compartment Block (40 mL of 1.5% mepivacaine)
Number of subjects: 60
Study 10792094 — intervention group
Group type: COMPARATOR
Intervention: High ligation surgery
Number of subjects: 468
Study 10792094 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical high inguinal varicocelectomy (MHIV)
Number of subjects: 468
Study 8704686 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) induction course (9 x 10(6) U/m2/day for 5 days) followed by maintenance (0.9 x 10(6) U/m2/day for 10 days)
Number of subjects: 14
Study 8704686 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) therapy
Number of subjects: 14
Study 1677910 — intervention group
Group type: EXPERIMENTAL
Intervention: Ficoll fractionated and Mafosfamide purged cells (50 micrograms/ml/1 x 10e7 MN cells)
Number of subjects: 40
Study 1677910 — intervention group
Group type: COMPARATOR
Intervention: Untreated buffy-coat marrow derived cells
Number of subjects: 40
Study 6406454 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (50-450 mg/day to 300-750 mg/day)
Number of subjects: 0
Study 6406454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6406454 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (75-225 mg/day)
Number of subjects: 0
Study 31677349 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTp‐mefloquine (MQ)
Number of subjects: 914
Study 31677349 — intervention group
Group type: COMPARATOR
Intervention: IPTp‐sulphadoxine‐pyrimethamine (SP)
Number of subjects: 914
Study 31677349 — intervention group
Group type: COMPARATOR
Intervention: IPTp‐placebo
Number of subjects: 914
Study 30917561 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised decision-support tool (DST)
Number of subjects: 65
Study 30917561 — intervention group
Group type: COMPARATOR
Intervention: General recommendations (Control Group)
Number of subjects: 65
Study 28809389 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based support for management of pressure ulcers (12 weeks)
Number of subjects: 0
Study 28809389 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 26063787 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin 7.5%
Number of subjects: 60
Study 26063787 — intervention group
Group type: COMPARATOR
Intervention: Glucose 2.5%
Number of subjects: 60
Study 23726175 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 56
Study 21522088 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine hydrochloride
Number of subjects: 0
Study 21522088 — intervention group
Group type: COMPARATOR
Intervention: tramadol hydrochloride
Number of subjects: 0
Study 20137432 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training program (1 hour weekly for 12 weeks)
Number of subjects: 441
Study 16702893 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem-MR 12.5 mg
Number of subjects: 18
Study 16702893 — intervention group
Group type: COMPARATOR
Intervention: Flurazepam 30 mg
Number of subjects: 18
Study 16702893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 14769727 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency department treatment of COPD exacerbation
Number of subjects: 140
Study 14769727 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of urgent clinic or ED visits for COPD exacerbation in the past year
Number of subjects: 140
Study 14769727 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported activity limitation during the past 24 h
Number of subjects: 140
Study 14769727 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory rate at ED presentation
Number of subjects: 140
Study 11686543 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (25 mg/day)
Number of subjects: 16
Study 11686543 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (5 mg/day)
Number of subjects: 16
Study 9692119 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 0.5 mg kg-1
Number of subjects: 98
Study 9692119 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 1.0 mg kg-1
Number of subjects: 98
Study 9692119 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 2.0 mg kg-1
Number of subjects: 98
Study 7921938 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical epirubicin at a concentration of 1 mg/ml (n = 40)
Number of subjects: 81
Study 7921938 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical epirubicin at a concentration of 2 mg/ml (n = 41)
Number of subjects: 81
Study 7921938 — intervention group
Group type: COMPARATOR
Intervention: Intravesical epirubicin (both concentrations)
Number of subjects: 81
Study 2908134 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg bromazepam
Number of subjects: 12
Study 2908134 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg bromazepam
Number of subjects: 12
Study 2908134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31789558 — intervention group
Group type: EXPERIMENTAL
Intervention: SDT-informed weight-loss intervention (SDT-WL)
Number of subjects: 64
Study 31789558 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral weight loss (BWL)
Number of subjects: 64
Study 31789558 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (BWL and SDT-WL)
Number of subjects: 64
Study 31645468 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 64
Study 31645468 — intervention group
Group type: COMPARATOR
Intervention: Control focused attention
Number of subjects: 64
Study 27838660 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine inhaler
Number of subjects: 47
Study 27838660 — intervention group
Group type: COMPARATOR
Intervention: nicotine administration
Number of subjects: 47
Study 24831730 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based skill-building intervention consisting of six to eight 60-minute sessions led by a trained health educator.
Number of subjects: 75
Study 24831730 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group.
Number of subjects: 75
Study 24347903 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid fractionation (6GyX3 fractions on alternate days during the 1st week, followed by 2GyX5 daily fractions in the 2nd week)
Number of subjects: 45
Study 24347903 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionation (3GyX5 daily fractions for 2 consecutive weeks)
Number of subjects: 45
Study 22142767 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans fatty acids in phosphatidylethanolamine (PE)
Number of subjects: 241
Study 22142767 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) in phosphatidylethanolamine (PE)
Number of subjects: 241
Study 22142767 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans fatty acids and DHA correlation in phosphatidylcholine (PC)
Number of subjects: 241